Beyond simply changing numbers on a biomarker lab report, this fundamental restoration of redox balance translated into profound, measurable physical improvements for the participants
The results showed a significant decrease in mean body weight, with a reduction of 12.1% compared to the placebo group
The U.S., which is among the key markets of GLP-1 drugs biosimilars, has benefited from rising expenditure on healthcare as well as the need for advanced treatments for metabolic diseases
The original Merck data showed 1.6 kg fat-free mass increase over 12 months in healthy elderly subjects (N=65) 8
All content is for informational purposes only and not a substitute for medical advice
Rudwaleit M, van der Heijde D, Landewe R, et al